Comparing axi-cel and standard of care in relapsed/refractory large B-cell lymphoma: a review of recent data on Q-TWiST, survival insights, and chimeric antigen receptor T-cell therapy considerations

Ann Palliat Med. 2024 Jan;13(1):190-193. doi: 10.21037/apm-23-493. Epub 2023 Nov 20.

Authors

Jean El-Cheikh¹, Mustafa Saleh¹, Zora Marjanovic², Tamim Alsuliman²

Affiliations

¹ Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
² Department of Hematology and Cell Therapy, Saint Antoine Hospital, AP-HP Sorbonne University, Paris, France.

PMID: 37993403
DOI: 10.21037/apm-23-493

No abstract available

Keywords: Chimeric antigen receptor T-cell (CAR-T); large B-cell lymphoma (LBCL); relapsed/refractory (R/R).

Publication types

Review

MeSH terms

Cell- and Tissue-Based Therapy
Humans
Lymphoma, Large B-Cell, Diffuse* / therapy
Receptors, Chimeric Antigen* / therapeutic use
Standard of Care

Substances

Receptors, Chimeric Antigen